Literature DB >> 11071109

Expression of OX40 and OX40 ligand (gp34) in the normal and myasthenic thymus.

J Onodera1, T Nagata, K Fujihara, M Ohuchi, N Ishii, K Sugamura, Y Itoyama.   

Abstract

OBJECTIVES: To examine the expression of OX40, an activated memory T-cell marker, and its ligand (OX40L), a set of molecules for T-cell-B-cell interaction, and other lymphocyte activation markers in the thymuses of myasthenia gravis (MG) and controls.
MATERIAL AND METHODS: We studied the expression of OX40, OX40L, IL-2Ralpha and HLA-DR in the thymic tissues of MG and controls using immunocytochemistry and flowcytometry.
RESULTS: In both hyperplastic thymus of MG and control thymus, OX40+ cells were scattered mainly in the medulla with much fewer OX40L+ cells being distributed in the corticomedullary junctions. IL-2Ralpha and HLA-DR were expressed in the medulla at higher frequencies as compared with OX40 in controls as well as MG. In contrast, the numbers of OX40+ cells around the germinal centers (GC) were significantly greater than those of control thymuses, and some mononuclear cells in GC were OX40L+. A considerable number of OX40+ cells were seen in the thymic tissues adjacent to thymomas. OX40+ cells were CD4+ CD8- or CD4+ CD8+ and were mostly HLA-DR-. (The coexpression of OX40 and IL-2Ralpha on activated CD4+ T cells was previously reported.)
CONCLUSION: OX40, expressed in a fraction of activated CD4+ T cells, may be upregulated in thymic tissues adjacent to GC and thymoma in MG, and OX40 may interact with OX40L in GC to enhance anti-acetylcholine receptor antibody production in MG.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11071109     DOI: 10.1034/j.1600-0404.2000.102004236.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  4 in total

1.  Detailed analysis of gene expression during development of T cell lineages in the thymus.

Authors:  Nami McCarty; Mari L Shinohara; Linrong Lu; Harvey Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-09       Impact factor: 11.205

2.  Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis.

Authors:  Zhao Xiaoyan; R Pirskanen; V Malmstrom; A K Lefvert
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

3.  Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis.

Authors:  Xiaoling Zhou; Xiaoyuan Wang; Yanzheng Gu; Lan Chen; Yueping Shen; Jingluan Tian; Chen Shujun; Mingyuan Wang; Xiaoyu Duan; Hanqing Gao; Xiaopei Ji; Qi Fang; Xueguang Zhang; Qun Xue
Journal:  J Immunol Res       Date:  2022-02-28       Impact factor: 4.818

Review 4.  OX40, OX40L and Autoimmunity: a Comprehensive Review.

Authors:  Gwilym J Webb; Gideon M Hirschfield; Peter J L Lane
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.